Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Ferrari, C. Stroh, K. Schulze-Osthoff (1999)
P2X7/P2Z Purinoreceptor-mediated Activation of Transcription Factor NFAT in Microglial Cells*The Journal of Biological Chemistry, 274
Synthia Sun, Lian‐Bin Lin, A. Hung, Jon‐Son Kuo (1999)
ATP‐Stimulated Ca2+ Influx and Phospholipase D Activities of a Rat Brain‐Derived Type‐2 Astrocyte Cell Line, RBA‐2, Are Mediated Through P2X7 ReceptorsJournal of Neurochemistry, 73
Miran Kim, V. Spelta, J. Sim, R. North, A. Surprenant (2001)
Differential Assembly of Rat Purinergic P2X7 Receptor in Immune Cells of the Brain and Periphery*The Journal of Biological Chemistry, 276
S. Visentin, M. Renzi, C. Frank, A. Greco, G. Levi (1999)
Two different ionotropic receptors are activated by ATP in rat microgliaThe Journal of Physiology, 519
R. Coutinho-Silva, P. Persechini, R. Bisaggio, J. Perfettini, A. Neto, J. Kanellopoulos, I. Motta-Ly, A. Dautry‐Varsat, D. Ojcius (1999)
P 2 Z / P 2 X 7 receptor-dependent apoptosis of dendritic cells
I. Hide, Masaya Tanaka, A. Inoue, K. Nakajima, S. Kohsaka, Kazuhide Inoue, Y. Nakata (2000)
Extracellular ATP Triggers Tumor Necrosis Factor‐α Release from Rat MicrogliaJournal of Neurochemistry, 75
H. Tokumitsu, T. Chijiwa, Masatoshi Hagiwara, Akihiro Mizutani, M. Terasawa, Hiroyoshi Hidaka (1990)
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.The Journal of biological chemistry, 265 8
Y. Born, London Ganten, Berlin Herken, B. Starke, Freiburg Br, Taylor (2001)
Purinergic and Pyrimidinergic Signalling I
J. Wiley, C. Gargett, W. Zhang, M. Snook, G. Jamieson (1998)
Partial agonists and antagonists reveal a second permeability state of human lymphocyte P2Z/P2X7 channel.The American journal of physiology, 275 5
R. North, E. Barnard (1997)
Nucleotide receptorsCurrent Opinion in Neurobiology, 7
L. Erb, K. Lustig, A. Ahmed, F. González, G. Weisman (1990)
Covalent incorporation of 3'-O-(4-benzoyl)benzoyl-ATP into a P2 purinoceptor in transformed mouse fibroblasts.The Journal of biological chemistry, 265 13
B. Fischer (1999)
Therapeutic applications of ATP-(P2)-receptors agonists and antagonistsExpert Opinion on Therapeutic Patents, 9
J. Wiley, C. Gargett, W. Zhang, M. Snook, G. Jamieson (1998)
Partial agonists and antagonists reveal a second permeability state of human lymphocyte P2Z/P2X7channel.American journal of physiology. Cell physiology, 275 5
A. Bringmann, T. Pannicke, V. Moll, I. Milenkovic, F. Faude, V. Enzmann, S. Wolf, A. Reichenbach (2001)
Upregulation of P2X(7) receptor currents in Müller glial cells during proliferative vitreoretinopathy.Investigative ophthalmology & visual science, 42 3
B. Fredholm, M. Abbracchio, G. Burnstock, G. Dubyak, T. Harden, K. Jacobson, U. Schwabe, M. Williams (1997)
Towards a revised nomenclature for P1 and P2 receptors.Trends in pharmacological sciences, 18 3
K. Jacobson, L. Knutsen (2001)
P1 and P2 Purine and Pyrimidine Receptor LigandsHandbook of experimental pharmacology, 151
D. Ferrari, A. Sala, P. Chiozzi, A. Morelli, S. Falzoni, G. Girolomoni, M. Idzko, S. Dichmann, J. Norgauer, F. Virgilio (2000)
The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine releaseThe FASEB Journal, 14
B. Bianchi, K. Lynch, E. Touma, W. Niforatos, E. Burgard, K. Alexander, Helen Park, Haixia Yu, R. Metzger, E. Kowaluk, M. Jarvis, T. Biesen (1999)
Pharmacological characterization of recombinant human and rat P2X receptor subtypes.European journal of pharmacology, 376 1-2
Lin-Hua Jiang, A. Mackenzie, R. North, A. Surprenant (2000)
Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors.Molecular pharmacology, 58 1
G. Torres, T. Egan, M. Voigt (1999)
Hetero-oligomeric Assembly of P2X Receptor SubunitsThe Journal of Biological Chemistry, 274
R. Coutinho-Silva, P. Persechini, R. Bisaggio, J. Perfettini, A. Neto, J. Kanellopoulos, I. Motta-Ly, A. Dautry‐Varsat, D. Ojcius (1999)
P2Z/P2X7receptor-dependent apoptosis of dendritic cells.American journal of physiology. Cell physiology, 276 5
K. Jacobson, Y. Kim, E. Camaioni, A. Rhee (1998)
Structure Activity Relationships of P2 Receptor Agonists and Antagonists
I. Chessell, J. Simon, A. Hibell, A. Michel, E. Barnard, P. Humphrey (1998)
Cloning and functional characterisation of the mouse P2X7 receptorFEBS Letters, 439
Benjamin Humphreys, Janet Rice, S. Kertesy, G. Dubyak (2000)
Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor.The Journal of biological chemistry, 275 35
I. Hide, M. Tanaka, A. Inoue, K. Nakajima, S. Kohsaka, K. Inoue, Y. Nakata (2000)
Extracellular ATP triggers tumor necrosis factor-alpha release from rat microglia.Journal of neurochemistry, 75 3
S. Bhagwat, M. Williams (1997)
P2 purine and pyrimidine receptors: emerging superfamilies of G-protein-coupled and ligand-gated ion channel receptorsEuropean Journal of Medicinal Chemistry, 32
Yun Hu, P. Fisette, L. Denlinger, A. Guadarrama, Julie Sommer, R. Proctor, P. Bertics (1998)
Purinergic Receptor Modulation of Lipopolysaccharide Signaling and Inducible Nitric-oxide Synthase Expression in RAW 264.7 Macrophages*The Journal of Biological Chemistry, 273
K. Jacobson, B. King, G. Burnstock (2000)
Pharmacological characterization of P2 (nucleotide) receptors
B. Humphreys, C. Virginio, A. Surprenant, J. Rice, G. Dubyak (1998)
Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues.Molecular pharmacology, 54 1
Yong‐Chul Kim, M. Zwart, Louis Chang, S. Moro, J. Künzel, N. Melman, A. IJzerman, K. Jacobson (1998)
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.Journal of medicinal chemistry, 41 15
C. Gargett, J. Wiley (1997)
The isoquinoline derivative KN‐62 a potent antagonist of the P2Z‐receptor of human lymphocytesBritish Journal of Pharmacology, 120
H. Puhl, P. Raman, C. Williams, R. Aronstam (1997)
Inhibition of M3 muscarinic acetylcholine receptor-mediated Ca2+ influx and intracellular Ca2+ mobilization in neuroblastoma cells by the Ca2+/calmodulin-dependent protein kinase inhibitor 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-trosyl]-4-phenylpiperazin e (KN-62).Biochemical pharmacology, 53 8
D. Ferrari, P. Chiozzi, S. Falzoni, M. Susino, G. Collo, G. Buell, F. Virgilio (1997)
ATP-mediated cytotoxicity in microglial cellsNeuropharmacology, 36
Michael Solle, J. Labasi, D. Perregaux, E. Stam, N. Petrushova, B. Koller, R. Griffiths, C. Gabel (2001)
Altered Cytokine Production in Mice Lacking P2X7Receptors*The Journal of Biological Chemistry, 276
(1997)
The P2 nucleotide receptors. Series “The receptors.
K. Jacobson, M. Jarvis, Michael Williams (2002)
Purine and pyrimidine (P2) receptors as drug targets.Journal of medicinal chemistry, 45 19
P. Baraldi, R. Romagnoli, M. Tabrizi, S. Falzoni, F. Virgilio (2000)
Synthesis of conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor.Bioorganic & medicinal chemistry letters, 10 7
Novel analogs of 1‐(N,O‐bis(5‐isoquinolinesulfonyl)‐N‐methyl‐L‐tyrosyl)‐4‐phenylpiperazine (KN‐62, 1) were synthesized and found to be potent antagonists in a functional assay, inhibition of ATP‐induced K+ efflux in HEK293 cells expressing recombinant human P2X7 receptors. Antagonism of murine P2X7 receptors was also observed. The analogs consisted of L‐tyrosine derivatives, of the general structure R1‐Tyr(OR2)‐piperazinyl‐R3, in which three positions were systematically varied in structure through facile acylation reactions. Each of the three positions was optimized in sequence through parallel synthesis alternating with biological evaluation, leading to the identification and optimization of potent P2X7 antagonists. The optimal groups at R1 were found to be large hydrophobic groups, linked to the ॅ‐amino position through carbamate, amide, or sulfonamide groups. The benzyloxycarbonyl (Cbz) group was preferred over most sulfonamides and other acyl groups examined, except for quinoline sulfonyl. At R2, an arylsulfonate ester was preferred, and the order of potency was p‐tolyl, p‐methoxyphenyl, phenyl > ॅ‐naphthyl, ॆ‐naphthyl. A benzoyl ester was of intermediate potency. Aliphatic esters and carbonate derivatives at the tyrosyl phenol were inactive, while a tyrosyl O‐benzyl ether was relatively potent. The most potent P2X7 receptor antagonists identified in this study contained Cbz at the R1 position, an aryl sulfonate at the R2 position, and various acyl groups at the R3 position. At R3, t‐butyloxycarbonyl‐ and benzoyl groups were preferred. The opening of the piperazinyl ring to an ethylene diamine moiety abolished antagonism. In concentration–response studies, a di‐isoquinolinyl, Boc derivative, 4 (MRS2306), displayed an IC50 value of 40 nM as an antagonist of P2X7 receptor‐mediated ion flux and was more potent than the reference compound 1. Nॅ‐Cbz, Boc‐piperazinyl derivatives, 11 (MRS2317), 22 (MRS2326), and 41 (MRS2409) were less potent than 1, with IC50 values of 200–300 nM. Drug Dev. Res. 54:75–87, 2001. © 2001 Wiley‐Liss, Inc.
Drug Development Research – Wiley
Published: Oct 1, 2001
Keywords: ion channels; nucleotides; structure activity relationships; purines; isoquinolines; KN‐62
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.